By which clinical phase should API methods be validated? And two, would you recommend the same guidance for drug product method validation for clinical phase?

Q7A does not specify when validation of methods is expected, i.e. during which clinical phase. But section 19.8 states that methods used should be scientifically sound. Your question on the drug product is outside the scope of Q7A.